Raj Singh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Raj Singh has a total of 170 co-authors. Here are the top co-authors by number of shared publications:
- Joshua David Palmer
Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA
7 shared publications Sanjeev Sharma
St Mary's Medical Center, Department of Radiation Oncology, Huntington, WV, USA
7 shared publicationsJoanne Davis
Radiosurgery Society, San Jose, CA, USA
5 shared publicationsEric J. Lehrer
Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota
4 shared publicationsJan Jenkins
Radiosurgery Society, San Jose, CA, USA
4 shared publicationsArjun Sahgal
Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
3 shared publications
Latest Publications
- Open Access
Clinical Outcomes and Patterns of Neurological Toxicity After Stereotactic Body Radiotherapy Reirradiation (reSBRT) of Spine Metastases Previously Treated with SBRT
Background/Objectives: Stereotactic body radiation therapy (SBRT) provides improved pain response and local control for spinal metastases. However, management of local failure after initial SBRT is challenging. We report institutional outcomes, dosimetry, and toxicity for reSBRT following SBRT. Methods: We retrospectively reviewed 61 lesions (55 patients) treated with reSBRT after prior SBRT. Both SBRT courses delivered a median dose of 27 Gy. Patients underwent clinical and radiological evaluation every three months. Toxicity was graded using CTCAE v5.0. Dosimetric parameters for the spinal cord (SC), cauda equina (CE), planning organ-at-risk volumes (PRV), and thecal sac were converted to equivalent dose in 2 Gy fractions (EQD2) using the linear–quadratic model (α/β = 2). Results: Median follow-up was 10.3 months. Forty lesions (65%) were cervicothoracic and 21 (35%) were lumbosacral. One- and two-year overall survival (OS) were 45% and 29%, respectively, and one- and two-year local control (LC) were 89% and 88%, respectively. Gastrointestinal primary tumors were associated with inferior LC (HR 2.41, 95% CI 1.11–5.23, p = 0.026). Fifteen patients (27%) reported myelitis/neuropathic symptoms during follow-up; four (7%) developed new post-radiation myelitis or neuropathy (RMN) without radiologic progression. Five patients (9%) developed vertebral compression fractures (VCF). Cumulative EQD2 was not significantly associated with RMN (p = 0.344); all affected patients had thecal sac EQD2 > 95.5 Gy and relevant nerve roots EQD2 > 108 Gy. Conclusions: ReSBRT provided a favorable LC with acceptable toxicity. High cumulative dose to the thecal sac and nerve roots may contribute to neurologic toxicity as peripheral nerve injury.
Open AccessClinical Outcomes and Patterns of Neurological Toxicity After Stereotactic Body Radiotherapy Reirradiation (reSBRT) of Spine Metastases Previously Treated with SBRT
Background/Objectives: Stereotactic body radiation therapy (SBRT) provides improved pain response and local control for spinal metastases. However, management of local failure after initial SBRT is challenging. We report institutional outcomes, dosimetry, and toxicity for reSBRT following SBRT. Methods: We retrospectively reviewed 61 lesions (55 patients) treated with reSBRT after prior SBRT. Both SBRT courses delivered a median dose of 27 Gy. Patients underwent clinical and radiological evaluation every three months. Toxicity was graded using CTCAE v5.0. Dosimetric parameters for the spinal cord (SC), cauda equina (CE), planning organ-at-risk volumes (PRV), and thecal sac were converted to equivalent dose in 2 Gy fractions (EQD2) using the linear–quadratic model (α/β = 2). Results: Median follow-up was 10.3 months. Forty lesions (65%) were cervicothoracic and 21 (35%) were lumbosacral. One- and two-year overall survival (OS) were 45% and 29%, respectively, and one- and two-year local control (LC) were 89% and 88%, respectively. Gastrointestinal primary tumors were associated with inferior LC (HR 2.41, 95% CI 1.11–5.23, p = 0.026). Fifteen patients (27%) reported myelitis/neuropathic symptoms during follow-up; four (7%) developed new post-radiation myelitis or neuropathy (RMN) without radiologic progression. Five patients (9%) developed vertebral compression fractures (VCF). Cumulative EQD2 was not significantly associated with RMN (p = 0.344); all affected patients had thecal sac EQD2 > 95.5 Gy and relevant nerve roots EQD2 > 108 Gy. Conclusions: ReSBRT provided a favorable LC with acceptable toxicity. High cumulative dose to the thecal sac and nerve roots may contribute to neurologic toxicity as peripheral nerve injury.
- 7 April 2026
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 125 (3) , 696-705
Improved Progression-Free Survival Following Dose-Escalated Versus Standard-Dose Postoperative Radiation Therapy for High-Risk Meningiomas: An International Multicenter Individual Patient–Level Meta-Analysis (FIRESTORM)
- 7 April 2026
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 125 (3) , 696-705
Improved Progression-Free Survival Following Dose-Escalated Versus Standard-Dose Postoperative Radiation Therapy for High-Risk Meningiomas: An International Multicenter Individual Patient–Level Meta-Analysis (FIRESTORM)
- Open Access
- 21 July 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (7) , 1778
Radiomics and Radiogenomics in Differentiating Progression, Pseudoprogression, and Radiation Necrosis in Gliomas
Over recent decades, significant advancements have been made in the treatment and imaging of gliomas. Conventional imaging techniques, such as MRI and CT, play critical roles in glioma diagnosis and treatment but often fail to distinguish between tumor pseudoprogression (Psp) and radiation necrosis (RN) versus true progression (TP). Emerging fields like radiomics and radiogenomics are addressing these challenges by extracting quantitative features from medical images and correlating them with genomic data, respectively. This article will discuss several studies that show how radiomic features (RFs) can aid in better patient stratification and prognosis. Radiogenomics, particularly in predicting biomarkers such as MGMT promoter methylation and 1p/19q codeletion, shows potential in non-invasive diagnostics. Radiomics also offers tools for predicting tumor recurrence (rBT), essential for treatment management. Further research is needed to standardize these methods and integrate them into clinical practice. This review underscores radiomics and radiogenomics’ potential to revolutionize glioma management, marking a significant shift towards precision neuro-oncology.
- 21 July 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (7) , 1778
Open AccessRadiomics and Radiogenomics in Differentiating Progression, Pseudoprogression, and Radiation Necrosis in Gliomas
Over recent decades, significant advancements have been made in the treatment and imaging of gliomas. Conventional imaging techniques, such as MRI and CT, play critical roles in glioma diagnosis and treatment but often fail to distinguish between tumor pseudoprogression (Psp) and radiation necrosis (RN) versus true progression (TP). Emerging fields like radiomics and radiogenomics are addressing these challenges by extracting quantitative features from medical images and correlating them with genomic data, respectively. This article will discuss several studies that show how radiomic features (RFs) can aid in better patient stratification and prognosis. Radiogenomics, particularly in predicting biomarkers such as MGMT promoter methylation and 1p/19q codeletion, shows potential in non-invasive diagnostics. Radiomics also offers tools for predicting tumor recurrence (rBT), essential for treatment management. Further research is needed to standardize these methods and integrate them into clinical practice. This review underscores radiomics and radiogenomics’ potential to revolutionize glioma management, marking a significant shift towards precision neuro-oncology.
- Open Access
- 19 February 2025
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 206, 110795
Dosimetric predictors of toxicity for brainstem metastases and AVMs treated with stereotactic radiosurgery: An international, multi-institutional analysis
- 19 February 2025
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 206, 110795
Open AccessDosimetric predictors of toxicity for brainstem metastases and AVMs treated with stereotactic radiosurgery: An international, multi-institutional analysis
- 13 February 2025
- Published by Elsevier in Practical Radiation Oncology
- Vol. 15 (3) , e245-e257
The Impact of Margin Expansions on Local Control and Radionecrosis Following Stereotactic Radiosurgery for Brain Metastases: A Systematic Review and Meta-Analysis
- 13 February 2025
- Published by Elsevier in Practical Radiation Oncology
- Vol. 15 (3) , e245-e257
The Impact of Margin Expansions on Local Control and Radionecrosis Following Stereotactic Radiosurgery for Brain Metastases: A Systematic Review and Meta-Analysis
- 1 January 2025
- Vol. 9 (3) , 199-205
Stereotactic ablative radiation therapy for extracranial metastases from malignant melanoma: An international multi-institutional analysis.
To report on local control (LC), toxicity, and overall survival (OS) following stereotactic ablative radiation therapy (SABR) for extracranial metastases from malignant melanoma. The RSSearch® Patient Registry was searched for patients with extracranial melanoma metastases treated with SABR. LC was defined as the time from completion of SABR to the date of last radiographic follow-up with either stability or decrease in size of the treated metastasis or the date at which lesion growth was radiographically confirmed per RECIST criteria. Kaplan-Meier analyses were utilized to evaluate potential prognostic factors on univariate analyses (UVA) with log-rank tests followed by use of a Cox proportional hazards multivariate (MVA) model. There were 45 patients with 52 extracranial melanoma metastases treated with SABR. One- and 2-year LC rates were both 85.3% (95% CI: 67.9-93.7%) following SABR. On UVA, BED10 < 60 Gy was associated with poorer 1-year and 2-year LC (96% vs. 61.9%), which remained significant on MVA (hazard ratio [HR] = 7.06; p = 0.03). On UVA, pulmonary vs. non-pulmonary metastases were correlated with 1-year OS (84.5% vs. 57.4%; p = 0.05) and non-spinal vs. spinal metastases (74.3% vs. 56.3%; p = 0.02), though neither were significant on MVA. The incidence of treatment-related toxicity was 18.9%, all Grade 1-2. We recommend dose/fractionation schedules that meet or exceed BED10 ≥ 60 Gy when treating extracranial melanoma metastases with SABR.
- 1 January 2025
- Vol. 9 (3) , 199-205
Stereotactic ablative radiation therapy for extracranial metastases from malignant melanoma: An international multi-institutional analysis.
To report on local control (LC), toxicity, and overall survival (OS) following stereotactic ablative radiation therapy (SABR) for extracranial metastases from malignant melanoma. The RSSearch® Patient Registry was searched for patients with extracranial melanoma metastases treated with SABR. LC was defined as the time from completion of SABR to the date of last radiographic follow-up with either stability or decrease in size of the treated metastasis or the date at which lesion growth was radiographically confirmed per RECIST criteria. Kaplan-Meier analyses were utilized to evaluate potential prognostic factors on univariate analyses (UVA) with log-rank tests followed by use of a Cox proportional hazards multivariate (MVA) model. There were 45 patients with 52 extracranial melanoma metastases treated with SABR. One- and 2-year LC rates were both 85.3% (95% CI: 67.9-93.7%) following SABR. On UVA, BED10 < 60 Gy was associated with poorer 1-year and 2-year LC (96% vs. 61.9%), which remained significant on MVA (hazard ratio [HR] = 7.06; p = 0.03). On UVA, pulmonary vs. non-pulmonary metastases were correlated with 1-year OS (84.5% vs. 57.4%; p = 0.05) and non-spinal vs. spinal metastases (74.3% vs. 56.3%; p = 0.02), though neither were significant on MVA. The incidence of treatment-related toxicity was 18.9%, all Grade 1-2. We recommend dose/fractionation schedules that meet or exceed BED10 ≥ 60 Gy when treating extracranial melanoma metastases with SABR.
- 1 January 2025
- Vol. 9 (3) , 215-226
Stereotactic ablative radiation therapy for pulmonary metastases from sarcoma primaries: A systematic review and meta-analysis of safety and efficacy.
Though promising retrospective and prospective studies have reported on stereotactic ablative radiation therapy(SABR) for management of lung metastases from sarcoma primaries, they are limited by small patient numbers. The primary outcomes of interest were 1-year and 2-year local control (LC) and Grade 3-5 toxicities. Secondary outcomes were 1-year overall survival (OS) and 2-year OS. Weighted random effects meta-analyses using the DerSimonian and Laird methods were performed to calculate effect sizes. Thirteen studies were identified with 533 patients and 940 lung metastases. The median prescription dose was 50 Gy (range: 48-60 Gy) in 5 fractions (range: 4-10). Following SABR, 1- and 2-year pooled LC rates were 97% (95% CI: 95-98%) and 91% (95% CI: 88-95%), respectively. Pooled 1- and 2-year OS rates were 85% (95% CI: 80-90%) and 68% (95% CI: 57-80%), respectively. The estimated incidence of Grade 3-5 toxicities following SABR was 0.1% (95% CI: 0-0.5%). SABR for sarcoma pulmonary metastases resulted in excellent LC with minimal toxicities.
- 1 January 2025
- Vol. 9 (3) , 215-226
Stereotactic ablative radiation therapy for pulmonary metastases from sarcoma primaries: A systematic review and meta-analysis of safety and efficacy.
Though promising retrospective and prospective studies have reported on stereotactic ablative radiation therapy(SABR) for management of lung metastases from sarcoma primaries, they are limited by small patient numbers. The primary outcomes of interest were 1-year and 2-year local control (LC) and Grade 3-5 toxicities. Secondary outcomes were 1-year overall survival (OS) and 2-year OS. Weighted random effects meta-analyses using the DerSimonian and Laird methods were performed to calculate effect sizes. Thirteen studies were identified with 533 patients and 940 lung metastases. The median prescription dose was 50 Gy (range: 48-60 Gy) in 5 fractions (range: 4-10). Following SABR, 1- and 2-year pooled LC rates were 97% (95% CI: 95-98%) and 91% (95% CI: 88-95%), respectively. Pooled 1- and 2-year OS rates were 85% (95% CI: 80-90%) and 68% (95% CI: 57-80%), respectively. The estimated incidence of Grade 3-5 toxicities following SABR was 0.1% (95% CI: 0-0.5%). SABR for sarcoma pulmonary metastases resulted in excellent LC with minimal toxicities.
- Open Access
Disease Control and Toxicity Outcomes after Stereotactic Ablative Radiation Therapy for Recurrent and/or Metastatic Cancers in Young-Adult and Pediatric Patients
Background: Pediatric patients with metastatic and/or recurrent solid tumors have poor survival outcomes despite standard-of-care systemic therapy. Stereotactic ablative radiation therapy (SABR) may improve tumor control. We report the outcomes with the use of SABR in our pediatric solid tumor population. Methods: This was a single-institutional study in patients < 30 years treated with SABR. The primary endpoint was local control (LC), while the secondary endpoints were progression-free survival (PFS), overall survival (OS), and toxicity. The survival analysis was performed using Kaplan–Meier estimates in R v4.2.3. Results: In total, 48 patients receiving 135 SABR courses were included. The median age was 15.6 years (interquartile range, IQR 14–23 y) and the median follow-up was 18.1 months (IQR: 7.7–29.1). The median SABR dose was 30 Gy (IQR 25–35 Gy). The most common primary histologies were Ewing sarcoma (25%), rhabdomyosarcoma (17%), osteosarcoma (13%), and central nervous system (CNS) gliomas (13%). Furthermore, 57% of patients had oligometastatic disease (≤5 lesions) at the time of SABR. The one-year LC, PFS, and OS rates were 94%, 22%, and 70%, respectively. No grade 4 or higher toxicities were observed, while the rates of any grade 1, 2, and 3 toxicities were 11.8%, 3.7%, and 4.4%, respectively. Patients with oligometastatic disease, lung, or brain metastases and those who underwent surgery for a metastatic site had a significantly longer PFS. LC at 1-year was significantly higher for patients with a sarcoma histology (95.7% vs. 86.5%, p = 0.01) and for those who received a biological equivalent dose (BED10) > 48 Gy (100% vs. 91.2%, p = 0.001). Conclusions: SABR is well tolerated in pediatric patients with 1-year local failure and OS rates of <10% and 70%, respectively. Future studies evaluating SABR in combination with systemic therapy are needed to address progression outside of the irradiated field.
Open AccessDisease Control and Toxicity Outcomes after Stereotactic Ablative Radiation Therapy for Recurrent and/or Metastatic Cancers in Young-Adult and Pediatric Patients
Background: Pediatric patients with metastatic and/or recurrent solid tumors have poor survival outcomes despite standard-of-care systemic therapy. Stereotactic ablative radiation therapy (SABR) may improve tumor control. We report the outcomes with the use of SABR in our pediatric solid tumor population. Methods: This was a single-institutional study in patients < 30 years treated with SABR. The primary endpoint was local control (LC), while the secondary endpoints were progression-free survival (PFS), overall survival (OS), and toxicity. The survival analysis was performed using Kaplan–Meier estimates in R v4.2.3. Results: In total, 48 patients receiving 135 SABR courses were included. The median age was 15.6 years (interquartile range, IQR 14–23 y) and the median follow-up was 18.1 months (IQR: 7.7–29.1). The median SABR dose was 30 Gy (IQR 25–35 Gy). The most common primary histologies were Ewing sarcoma (25%), rhabdomyosarcoma (17%), osteosarcoma (13%), and central nervous system (CNS) gliomas (13%). Furthermore, 57% of patients had oligometastatic disease (≤5 lesions) at the time of SABR. The one-year LC, PFS, and OS rates were 94%, 22%, and 70%, respectively. No grade 4 or higher toxicities were observed, while the rates of any grade 1, 2, and 3 toxicities were 11.8%, 3.7%, and 4.4%, respectively. Patients with oligometastatic disease, lung, or brain metastases and those who underwent surgery for a metastatic site had a significantly longer PFS. LC at 1-year was significantly higher for patients with a sarcoma histology (95.7% vs. 86.5%, p = 0.01) and for those who received a biological equivalent dose (BED10) > 48 Gy (100% vs. 91.2%, p = 0.001). Conclusions: SABR is well tolerated in pediatric patients with 1-year local failure and OS rates of <10% and 70%, respectively. Future studies evaluating SABR in combination with systemic therapy are needed to address progression outside of the irradiated field.
- 12 January 2024
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 119 (4) , 1099-1109
Clinical Outcomes After Stereotactic Body Radiation Therapy for Nonspinal Bone Metastases: A Systematic Review and Meta-analysis
- 12 January 2024
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 119 (4) , 1099-1109
Clinical Outcomes After Stereotactic Body Radiation Therapy for Nonspinal Bone Metastases: A Systematic Review and Meta-analysis